CARDINAL HEALTH INC company mark

CARDINAL HEALTH INC Business Intelligence Report

Latest Annual Report • Financial Analysis • Management Commentary • Earnings Summary • Official Filings
Official Annual + Quarterly Filings · AI Business Intelligence
NASDAQ/NYSE: CAH
Sector: Healthcare
Industry: Medical Distribution
Source: SEC EDGAR
Last Updated: 18 Jun 2026
Business Intelligence Report Verdict
Weak
Outlook: Cautious

Quality Scores

Business Compounding
25/100
Compounder
42/100
Management
60/100
Governance
40/100
Cash Flow
82/100

Latest Quarterly Earnings Summary

No quarterly summary available yet.

AI Summary

Cardinal Health operates as a critical pillar in the healthcare supply chain, yet its financial profile over the last decade reveals a business struggling with structural headwinds and massive legal liabilities. While revenue has ballooned from approximately $31B to over $220B, this top-line expansion has not translated into stable bottom-line growth, evidenced by erratic net income and technical insolvency. The company's balance sheet is currently impaired with negative stockholders' equity, primarily driven by multi-billion dollar opioid-related litigation settlements and asset write-downs.…

Key Changes in FY2026

Cardinal Health has undergone a massive scale transformation, growing revenue from approximately $31B to over $222B in a decade, driven by its role as a backbone for retail pharmacies and healthcare providers. The evolution from a diversified healthcare services company to a high-volume pharmaceutical distributor was accelerated by the integration of large-scale contracts with major pharmacy retailers. The company has moved up the value chain by expanding its specialty pharmaceutical services and third-party logistics (3PL) offerings. Digital transformation efforts, including the 'NaviHealth' platform and enhanced inventory management software, have improved customer stickiness. Despite incredible revenue growth, the mix shift toward lower-margin specialty products has pressured overall…

Management Commentary

Management has navigated an incredibly turbulent decade characterized by systemic industry litigation and shifting reimbursement models. While they have successfully maintained operational continuity and scaled the Pharmaceutical segment, their execution in the Medical segment has been disappointing, leading to recurring 'turnaround' narratives. Transparency in MD&A has improved as the company moved toward 'non-GAAP' reporting to distance themselves from legal costs, but this often masks the true economic toll on the business. The leadership has been criticized for slow reaction times to the generic deflation cycle and for the sheer scale of the legal liabilities incurred under earlier oversight. Current management is focused on a 'simplify and focus' strategy, which is the correct path…

Financial Highlights

The financial trajectory is a study in volume growth versus margin erosion. Revenue grew at a staggering pace, particularly after 2020, yet operating income plummeted into negative territory twice in the last decade (2020 and 2022). Operating margins are exceptionally thin, often below 1%, leaving virtually no room for error or external shocks. The company reported a massive $1.17B loss in 2018 and a $933M loss in 2022, highlighting the impact of non-recurring impairment charges and legal accruals. Net Worth has collapsed from $6.55B in 2016 to a deficit of $2.78B in 2025, a classic red flag signaling that historic losses and shareholder payouts have exceeded retained earnings. This technical insolvency makes the company's financial health entirely dependent on continuous access to debt…

Major Opportunities

  • Secular tailwinds in US healthcare spending
  • Critical infrastructure role in drug distribution
  • Significant revenue scale exceeding $200B

Major Risks

  • Structural negative Stockholders Equity
  • Extremely thin net margins (often <1%)
  • Massive multi-billion opioid litigation settlements

About CARDINAL HEALTH INC's Annual Report & Financial Performance

The latest CARDINAL HEALTH INC annual report (FY2026) is the company's flagship annual disclosure, filed with SEC EDGAR. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.

What this CARDINAL HEALTH INC research covers

  • Fundamental & business analysis
  • Financial statements & performance
  • Management commentary & discussion
  • Corporate governance & auditor report
  • Cash flow analysis & capital allocation
  • Valuation analysis & business quality
  • Growth analysis & competitive position
  • Risk, SWOT & moat analysis
  • Quarterly earnings & conference-call summary
  • Sector, industry & peer comparison
  • Latest official company filings
  • Business outlook & long-term growth

CARDINAL HEALTH INC — Frequently Asked Questions

Explore more CARDINAL HEALTH INC research

AI Top Insights — Premium

Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.